Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 89

recruiting
3 987
countries
28
conditions
2 109

1 063 trials match your criteria

Study on the Safety and Effectiveness of Volrustomig with a Drug Combination for Patients with Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Study on Imatinib and Chemotherapy Combination for Children with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Crisantaspase

Study on Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab

Plasma cell myeloma

Not recruiting

Study on the Effectiveness of Bortezomib, Melphalan, and Prednisone vs. Carfilzomib, Lenalidomide, and Dexamethasone in Older Adults with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:65+ years
  • Substances:Bortezomib

Study Comparing Docetaxel Alone and Docetaxel with Radium-223 for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Radium RA 223 dichloride

Study on Datopotamab Deruxtecan and Osimertinib for Patients with Advanced Non-Small Cell Lung Cancer After Osimertinib Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Study of Tiragolumab and Atezolizumab for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.